MedPath

Diltiazem

Generic Name
Diltiazem
Brand Names
Cardizem, Cartia, Matzim, Taztia, Tiadylt, Tiazac
Drug Type
Small Molecule
Chemical Formula
C22H26N2O4S
CAS Number
42399-41-7
Unique Ingredient Identifier
EE92BBP03H
Background

Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as nifedipine, that preferentially act on vascular smooth muscle and verapamil that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation, atrial flutter. Apart from its main FDA-approved indications, diltiazem has also been used for numerous off-label indications, such as anal fissures (in topical formulations), migraine prophylaxis, pulmonary hypertension, and rest-related cramps in the lower extremities. Typically available in extended-release oral and intravenous formulations, diltiazem is marketed under various brand names with Cardizem and Tiazac being the most common ones.

Indication

Oral

Indicated for the management of hypertension, to lower blood pressure, alone or in combination with other antihypertensive agents.

Indicated for use to improve exercise tolerance in patients with chronic stable angina.

Indicated for the management of variant angina (Prinzmetal's angina).

Intravenous

Indicated for the short-term management of atrial fibrillation or atrial flutter for temporary control of rapid ventricular rate.

Indicated for the rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome.

Off-label

Indicated for off-label uses in anal fissures (as topical formulation), migraine prophylaxis, cramps in lower leg related to rest, pulmonary hypertension, idiopathic dilated cardiomyopathy, and proteinuria associated with diabetic nephropathy.

Associated Conditions
Angina Pectoris, Variant, Anginal Pain, Atrial Fibrillation, Atrial Flutter, Chronic Stable Angina Pectoris, Dilated Cardiomyopathies, Idiopathic, Fissure;Anal, Hypertension, Paroxysmal Supraventricular Tachycardia (PSVT), Proteinuria, Pulmonary Hypertension (PH), Leg cramps, Prophylaxis of migraine headaches

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Phase 1
Active, not recruiting
Conditions
Healthy
Interventions
First Posted Date
2025-02-11
Last Posted Date
2025-05-15
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
30
Registration Number
NCT06818968
Locations
🇺🇸

Fortrea CRU, Madison ( Site 0001), Madison, Wisconsin, United States

A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-11-25
Last Posted Date
2024-11-25
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
16
Registration Number
NCT06703463
Locations
🇺🇸

Celerion (Site 0002), Lincoln, Nebraska, United States

A Clinical Study of MK-4318 and Diltiazem in Healthy People (MK-4318-003)

Phase 1
Completed
Conditions
Healthy
Pain
Interventions
First Posted Date
2024-11-18
Last Posted Date
2024-11-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
19
Registration Number
NCT06692647
Locations
🇺🇸

Labcorb CRU, Madison (Site 0001), Madison, Wisconsin, United States

A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2024-10-28
Last Posted Date
2024-10-28
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
14
Registration Number
NCT06662396
Locations
🇺🇸

ICON (Site 0001), Lenexa, Kansas, United States

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

First Posted Date
2024-08-15
Last Posted Date
2024-10-11
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
12
Registration Number
NCT06554639
Locations
🇺🇸

Celerion ( Site 0001), Tempe, Arizona, United States

Diltiazem in Jervell and Lange-Nielsen Syndrome

Phase 4
Completed
Conditions
Jervell and Lange Nielsen Syndrome
Interventions
First Posted Date
2024-08-02
Last Posted Date
2024-12-19
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
1
Registration Number
NCT06534671
Locations
🇺🇸

Vanderbilt University Medical Center, Nashville, Tennessee, United States

Oral Bisoprolol Vs IV Diltiazem in Atrial Fibrillation or Flutter with Rapid Ventricular Rate.

Phase 3
Not yet recruiting
Conditions
Atrial Fibrillation with Rapid Ventricular Response
Atrial Flutter with Rapid Ventricular Response
Interventions
First Posted Date
2024-02-23
Last Posted Date
2025-03-14
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
60
Registration Number
NCT06276127
Locations
🇴🇲

Sultan Qaboos University Hospital, Muscat, Al-khod, Oman

Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia

Phase 2
Withdrawn
Conditions
COVID-19
Interventions
First Posted Date
2022-10-03
Last Posted Date
2023-05-26
Lead Sponsor
Hospices Civils de Lyon
Registration Number
NCT05563168
Locations
🇫🇷

Service des Maladies Infectieuses et Tropicales, Fort-de-France, France

🇫🇷

respiratory department Amiens Hospital, Amiens, France

🇫🇷

Service de Maladies infectieuses et tropicales, Amiens, France

and more 18 locations

Randomized Trial to Examine a Differential Therapeutic Response in Symptomatic Patients With Non-obstructive Coronary Artery Disease

Phase 4
Conditions
Microvascular Angina
Vasospastic Angina
Vasospasm, Coronary
Coronary Microvascular Dysfunction
Coronary Artery Disease
Prinzmetal Angina
Interventions
First Posted Date
2022-03-24
Last Posted Date
2022-03-24
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
132
Registration Number
NCT05294887
Locations
🇨🇭

Universitäres Herzzentrum Zürich, Universitätsspital Zürich, Zürich, Switzerland

🇩🇪

Kerckhoff-Klinik gGmbH, Bad Nauheim, Germany

🇩🇪

Herz- und Diabeteszentrum NRW, Bad Oeynhausen, Germany

and more 12 locations

Heart Rate Controller in Computed Tomography Coronary Angiography

Phase 4
Conditions
Heart Rate
Coronary Computed Tomography Angiography
Interventions
First Posted Date
2022-03-02
Last Posted Date
2022-05-17
Lead Sponsor
Mahidol University
Target Recruit Count
246
Registration Number
NCT05261464
Locations
🇹🇭

Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital Mahidol University, Bangkok, Bangkoknoi, Thailand

© Copyright 2025. All Rights Reserved by MedPath